GSK PLC Sponsored ADR $GSK Shares Purchased by Keystone Financial Planning Inc.

Key Points

• Keystone Financial Planning increased its GSK stake by 3,114.8% in the second quarter, adding 189,506 shares to own 195,590 shares valued at approximately $10.25 million. Institutional investors and hedge funds collectively own 15.74% of GSK.
• GSK reported quarterly EPS of $1.36, exceeding estimates of $1.27, while revenue rose 5.3% year over year to $11.14 billion. The company guided for fiscal 2026 EPS of $4.90–$5.00.
• GSK raised its quarterly dividend to $0.4515 per share, equivalent to an annualized $1.81 dividend and a 3.7% yield. Analysts maintain a consensus “Hold” rating with a $53 price target.

Keystone Financial Planning Inc. raised its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 3,114.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 195,590 shares of the pharmaceutical company's stock after purchasing an additional 189,506 shares during the quarter. GSK accounts for about 2.6% of Keystone Financial Planning Inc.'s holdings, making the stock its 5th biggest position. Keystone Financial Planning Inc.'s holdings in GSK were worth $10,253,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GSK. Brighton Jones LLC purchased a new stake in shares of GSK in the fourth quarter valued at approximately $528,000. AQR Capital Management LLC raised its position in GSK by 84.4% in the first quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company's stock worth $1,559,000 after acquiring an additional 18,420 shares in the last quarter. Empowered Funds LLC lifted its holdings in GSK by 2.1% in the first quarter. Empowered Funds LLC now owns 79,174 shares of the pharmaceutical company's stock valued at $3,067,000 after acquiring an additional 1,598 shares during the period. Rhumbline Advisers lifted its holdings in GSK by 20.7% in the second quarter. Rhumbline Advisers now owns 22,209 shares of the pharmaceutical company's stock valued at $853,000 after acquiring an additional 3,806 shares during the period. Finally, Gabelli Funds LLC boosted its position in shares of GSK by 17.8% during the 2nd quarter. Gabelli Funds LLC now owns 7,960 shares of the pharmaceutical company's stock worth $306,000 after purchasing an additional 1,200 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Trading Up 0.2%

Shares of GSK stock opened at $48.66 on Thursday. GSK PLC Sponsored ADR has a fifty-two week low of $39.29 and a fifty-two week high of $61.69. The stock has a market cap of $98.42 billion, a P/E ratio of 15.22, a P/E/G ratio of 2.03 and a beta of 0.35. The business has a fifty day simple moving average of $51.51 and a 200-day simple moving average of $52.91. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.09. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%.The business's revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, analysts forecast that GSK PLC Sponsored ADR will post 4.81 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be issued a $0.4515 dividend. This represents a $1.81 annualized dividend and a dividend yield of 3.7%. This is a boost from GSK's previous quarterly dividend of $0.44. The ex-dividend date of this dividend is Friday, August 14th. GSK's payout ratio is currently 55.63%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Royal Bank Of Canada began coverage on shares of GSK in a research note on Tuesday. They set a "sector perform" rating on the stock. HSBC raised shares of GSK from a "reduce" rating to a "hold" rating in a report on Monday, July 6th. Morgan Stanley restated an "underweight" rating on shares of GSK in a research report on Tuesday, August 25th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of GSK in a report on Thursday, July 30th. Finally, Jefferies Financial Group upgraded shares of GSK to a "strong-buy" rating in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $53.00.

GSK Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.